Advances in translational research of the rare cancer type adrenocortical carcinoma
Adrenocortical carcinoma is a rare malignancy with an annual worldwide incidence of 1–2
cases per 1 million and a 5-year survival rate of< 60%. Although adrenocortical carcinoma is …
cases per 1 million and a 5-year survival rate of< 60%. Although adrenocortical carcinoma is …
Update on biology and genomics of adrenocortical carcinomas: rationale for emerging therapies
The adrenal glands are paired endocrine organs that produce steroid hormones and
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …
A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma
Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from
steroidogenic cells within the adrenal cortex. In this study, we have assessed for the …
steroidogenic cells within the adrenal cortex. In this study, we have assessed for the …
Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction
I Weigand, J Schreiner, F Röhrig, N Sun… - Cell death & …, 2020 - nature.com
Conditions of impaired adrenal function and tissue destruction, such as in Addison's
disease, and treatment resistance of adrenocortical carcinoma (ACC) necessitate improved …
disease, and treatment resistance of adrenocortical carcinoma (ACC) necessitate improved …
Development of an adrenocortical cancer humanized mouse model to characterize anti-PD1 effects on tumor microenvironment
J Lang, A Capasso, KR Jordan… - The Journal of …, 2020 - academic.oup.com
Context Although the development of immune checkpoint inhibitors has transformed
treatment strategies of several human malignancies, research models to study …
treatment strategies of several human malignancies, research models to study …
An update on adrenocortical cell lines of human origin
S Sigala, E Rossini, A Abate, M Tamburello… - Endocrine, 2022 - Springer
Adrenocortical carcinoma (ACC) is a rare, heterogenous and highly malignant disease.
Management of ACC is dependent on disease stage with complete surgical resection as the …
Management of ACC is dependent on disease stage with complete surgical resection as the …
Preclinical models of adrenocortical cancer
Simple Summary Adrenocortical cancer is a very rare form of endocrine cancer with dismal
prognosis. Preclinical models such as cell lines, organoids, and mouse models are essential …
prognosis. Preclinical models such as cell lines, organoids, and mouse models are essential …
A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity
Adrenocortical carcinoma (ACC) has a poor prognosis, and no new drugs have been
identified in decades. The absence of drug development can partly be attributed to a lack of …
identified in decades. The absence of drug development can partly be attributed to a lack of …
A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden
LS Landwehr, J Schreiner, S Appenzeller… - European journal of …, 2021 - academic.oup.com
Background The response of advanced adrenocortical carcinoma (ACC) to current
chemotherapies is unsatisfactory and a limited rate of response to immunotherapy was …
chemotherapies is unsatisfactory and a limited rate of response to immunotherapy was …
Molecular mechanisms of mitotane action in adrenocortical cancer based on in vitro studies
M Lo Iacono, S Puglisi, P Perotti, L Saba, J Petiti… - Cancers, 2021 - mdpi.com
Simple Summary Mitotane is the only approved drug for the treatment of advanced
adrenocortical carcinoma and for postoperative adjuvant therapy. It is known that mitotane …
adrenocortical carcinoma and for postoperative adjuvant therapy. It is known that mitotane …